First, the good news: Fresh Track’s atopic dermatitis treatment has strolled through a phase 1 study, a notable success for the first oral DYRK1A inhibitor to enter the clinic for an autoimmune ...
The Company is continuing to wind down its operations and resolve all outstanding liabilities. The Company currently has approximately 6.0 million outstanding shares and approximately 0.6 million ...
Fresh Tracks Therapeutics Inc. (Nasdaq: FRTX), the Boulder-based pharmaceutical company formerly called Brickell Biotech, saw both its top and bottom lines improve in the third quarter of 2022, a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results